Flulaval Quadrivalent Influenza Vaccine 2023
GSK's Flulaval Quadrivalent is an inactivated influenza vaccine from viruses propagated in hens' eggs. Each of the four influenza viruses is produced and purified separately. The viruses are inactivated with ultraviolet light treatment followed by formaldehyde treatment, purified by centrifugation, and disrupted with sodium deoxycholate. Flulaval Quadrivalent (STN: BL 125163) is formulated without preservatives and does not contain thimerosal, according to the U.S. Food and Drug Administration (FDA).
The World Health Organization (WHO) announced the flu vaccine composition for the 2023 southern hemisphere flu season. On March 7, 2023, the U.S. FDA presented the Influenza Virus Vaccine Strain Selection for the composition of the influenza vaccines for 2023-2024.
GSK confirmed on July 13, 2023, that it expects to distribute over 40 million doses of its influenza vaccine to the U.S. market. Both FLULAVAL QUADRIVALENT and FLUARIX QUADRIVALENT will be available in a 0.5mL, single-dose, pre-filled syringe and are indicated for patients six months and older for the current flu season in the U.S.
GlaxoSmithKline plc (GSK) is located in Brentford, United Kingdom, and Philadelphia, PA.
Flulaval Quadrivalent Indication
Flulaval Quadrivalent is indicated for active immunization to prevent disease caused by influenza A subtype and type B viruses in the vaccine. FLULAVAL QUADRIVALENT is approved for use in persons aged six months and older.
Flulaval Quadrivalent and COVID-19 Vaccines
The US Centers for Disease Control and Prevention (CDC) previously issued interim clinical considerations stating that 'COVID-19 vaccines and other vaccines, including influenza vaccines, can be administered without regard to timing.
Flulaval Quadrivalent Dosage
Flulaval Quadrivalent is approved for use in persons aged six months and older. Flulaval Quadrivalent is administered as an intramuscular injection. Do not administer Flulaval Quadrivalent to anyone with a history of severe allergic reactions (e.g., anaphylaxis) to any vaccine component, including egg protein, or following a previous dose of any influenza vaccine. For detailed dosage information, visit GSK.
Flulaval Quadrivalent Side Effects
Flulaval Quadrivalent is generally well-tolerated. Do not administer FLULAVAL QUADRIVALENT to anyone with a history of severe allergic reactions (e.g., anaphylaxis) to any vaccine component, including egg protein, or following a previous dose of any influenza vaccine. Suppose Guillain-Barré syndrome has occurred within six weeks of receipt of a prior influenza vaccine. In that case, the decision to give FLULAVAL QUADRIVALENT should be based on carefully considering the potential benefits and risks. Suppose you or your loved one has an adverse reaction to the vaccine. In that case, that information should be reported to VAERS, a U.S. passive reporting system that relies on individuals to send reports of their vaccine experiences. Anyone can submit a report to VAERS, including parents and patients. Furthermore, healthcare providers are required by law to report to VAERS.
Flulaval Quadrivalent News
September 12, 2023 - The U.S. CDC ACIP Releases 2023-2024 Influenza Vaccine Recommendations.
July 13, 2023 - GSK plc announced the availability of flu vaccines for the 2023-2024 season.
March 17, 2023 - The CDC weekly influenza surveillance reported seasonal influenza activity remains low nationally.
May 4, 2022 - Flu News Europe announced for week 16, of 39 countries and areas reporting on the intensity of influenza activity, 18 reported baseline intensity (across the Region), 14 reported low-intensity (across the Region), six reported medium-intensity (Denmark, Georgia, Kazakhstan, Latvia, Lithuania, and Romania), and one reported high-intensity (Estonia).
April 8, 2022 - The CDC FluView report indicated that Influenza activity increased nationally this week. Influenza activity is highest in the central and south-central regions of the country and is increasing in the northeastern regions.
November 11, 2021 - Despite increased influenza testing, levels continue to remain low, reported the WHO.
October 16, 2021 - The US CDC reported in week 41 that 0.1% of long-term care facilities reported > 1 influenza-positive test among residents. And no jurisdictions reported high or very high ILI activity.
October 7, 2021 - During week 40, the U.K. reported eight influenza-positive cases.
September 11, 2021 - Nationwide, during week 36, 2.3% of patient visits reported through ILINet were due to ILI. The percentage of patient visits for ILI remains below the baseline of 2.6% nationally.
September 4, 2021 - According to the US CDC, the percentages of visits for ILI reported in ILINet have been stable or decreasing among adult age groups (25-49 years, 50-64 years, and 65+ years) and may starting to stabilize among the younger age groups (0-4 years and 5-24 years).
August 26, 2021 - The U.S. FDA confirmed (30) lots of FluLaval Quadrivalent from I.D. Biomedical Corporation of Quebec has been released and is available for distribution in the USA.
July 26, 2021 - The global influenza vaccines market is projected to exceed the US$ 9.5 Billion mark by 2027 and present ample opportunities to the industry's players. In 2020, GlaxoSmithKline plc influenza vaccines (Fluarix/FluLaval) sales were up 35% from the previous year.
July 23, 2021 - GSK announced it started shipping its quadrivalent influenza vaccines to U.S. healthcare providers and pharmacies for the 2021-22 flu season. "GSK's focus continues to be increasing vaccination rates during the COVID-19 pandemic, and the flu vaccination is an integral part of that public health effort," said Judy Stewart, Senior Vice President and Head of U.S. Vaccines at GSK.
July 2, 2021 - The U.S. FDA issued a Supplement Approval letter to GSK for active immunization to prevent disease caused by influenza A subtype and type B viruses in the vaccine.
July 28, 2020 - GSK begins shipping a record number of its influenza vaccine doses for the 2020-21 season for the U.S. market. FLULAVAL QUADRIVALENT will be available in a 0.5mL, single-dose, pre-filled syringe and indicated for patients six months and older in line with CDC recommendations.
November 18, 2016 - GSK announced it had received approval from the U.S. Food and Drug Administration's (FDA) Center to expand the indication for FluLaval® Quadrivalent (Influenza Vaccine) to include use in children six months and older. Before this, the vaccine was only approved for active immunization against influenza A subtype and type B viruses in persons three years of age and older.
Flulaval Quadrivalent Clinical Trials
Flulaval Quadrivalent Influenza Vaccine has been tested in over 20 clinical trials.